MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 03-14-2026
Insulet Corporation Accounts Receivables 2011-2026 | PODD
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Insulet Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 161 M | 83.8 M | 69.3 M | 63.3 M | 53.4 M | 28.8 M | 42.5 M | 39.9 M | 33.1 M | 33.3 M | 23.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 23.2 M | 57.4 M |
Quarterly Accounts Receivables Insulet Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154 M | 135 M | 114 M | 100 M | 97.9 M | 95.3 M | 83.8 M | 83.8 M | 83.8 M | 69.3 M | 69.3 M | 69.3 M | 69.3 M | 63.3 M | 63.3 M | 63.3 M | 63.3 M | 53.4 M | 53.4 M | 53.4 M | 53.4 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 42.5 M | 42.5 M | 42.5 M | 42.5 M | 35.2 M | 39.9 M | 39.9 M | 39.9 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 33.3 M | 33.3 M | 33.3 M | 33.3 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | 23.2 M | 55.3 M |
Accounts Receivables of other stocks in the Medical devices industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
97.3 M | $ 11.75 | -3.29 % | $ 1.76 B |  USA |
 |
BioSig Technologies
BSGM
|
109 K | - | 37.08 % | $ 85.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
44.8 M | - | - | $ 3.31 B | USA |
 |
Delcath Systems
DCTH
|
11.7 M | $ 8.98 | -1.32 % | $ 322 M | USA |
 |
Aziyo Biologics
AZYO
|
1.73 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
11.4 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
2.37 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
455 K | - | -0.97 % | $ 54.4 M | USA |
 |
Conformis
CFMS
|
9.77 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
39.7 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
38.9 M | $ 6.32 | -2.02 % | $ 168 M | USA |
 |
Apollo Endosurgery
APEN
|
15 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
6.73 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
13.7 M | $ 100.97 | 1.78 % | $ 1.28 B | USA |
 |
Avinger
AVGR
|
1.01 M | - | -20.74 % | $ 369 K | USA |
 |
LivaNova PLC
LIVN
|
216 M | $ 62.4 | -1.33 % | $ 3.4 B |  Britain |
 |
LENSAR
LNSR
|
6.08 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
AxoGen
AXGN
|
26.2 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
248 M | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Medtronic PLC
MDT
|
6.52 B | $ 86.58 | -0.68 % | $ 111 B | USA |
 |
NanoVibronix
NAOV
|
98 K | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
24.7 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
InspireMD
NSPR
|
2.17 M | $ 1.79 | 3.47 % | $ 115 M |  Israel |
 |
Orthofix Medical
OFIX
|
136 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
Cytosorbents Corporation
CTSO
|
7.32 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
128 K | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
BIOLASE
BIOL
|
5.48 M | - | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
190 M | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
371 M | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
4.1 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
112 K | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
88 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
18.6 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
Quanterix Corporation
QTRX
|
30 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
53.8 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
28.3 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |